View All Attorneys

Attorneys

William N. Wofford

Bill is a corporate transactional lawyer and drug development entrepreneur. He leads the biopharmaceutical and life sciences practice at Hutchison, where his practice focuses on structuring and negotiating transactions for drug development, biotechnology, medical device and healthcare services companies and financial, strategic and philanthropic investors. Bill helps growing and established companies raise capital, acquire and out-license technology, collaborate with strategic partners and engage in mergers and acquisitions. He is also an investor in and advisor to various drug development companies and a principal with Arrivo Bioventures, a Research Triangle biopharmaceutical development company. Bill earned his B.A. and J.D. from the University of Virginia. He serves on the Board of Directors of the Eco Institute at Pickards Mountain and supports environmental, mental health and social justice causes. 

Recognition, Affiliations & Memberships

  • Co-author and Editor, Biotechnology and the Law (American Bar Association, 2007)
  • Board of Directors, SEBIO, 2009-2015
  • Member, Entrepreneurial Council for the Wake Forest University Translational Science Institute (TSI)
  • Best Lawyers in America, recognized annually since 2007
  • Member, Licensing Executives Society
  • Member, American Bar Association’s Business Section and Science and Technology Committee
  • Super Lawyers, 2006, 2008

Education

  • J.D., University of Virginia, 1994
  • B.A., University of Virginia, 1989

 Admissions

  • New York
  • North Carolina
  • Aerial BioPharma’s sale to Jazz Pharmaceuticals of the drug development candidate now known as “solriamfetol”
  • Clearside Biomedical’s (NASDAQ: CLSD) out-license of rights in Russia and neighboring countries to ophthalmic steroid program and various unpublished early stage collaborations
  • PocketSonics’ acquisition by Analogic
  • Arrivo Bioventures’ in-licenses of worldwide rights to antibody fragment portfolio from Delenex/CellMedica
  • Ascletis Pharma’s in-license of Chinese rights to clinical stage anti-viral programs
  • CureDuchenne’s investments in and collaborations with Bamboo Therapeutics (sold to Pfizer), Capricor Therapeutics, Exonics Therapeutics (including Exonics’ in-license of CRISPR technology from UTSW), Myotherix, Prosensa (sold to BioMarin) and RasRx
  • Innovate Biopharmaceuticals’ (NASDAQ: INNT) pre-IPO acquisition and in-license of drug candidates for celiac disease, NASH, Crohn's and ulcerative colitis
  • Midnight Pharma’s in-license of sleep drug candidate from Actelion
  • Velo Bio’s acquisition of clinical stage pre-eclampsia drug and subsequent option deal/partnership with AMAG Pharmaceuticals
  • Spyryx Biosciences’ IP license from UNC Chapel Hill, Series A financing and funding collaboration with the Cystic Fibrosis Foundation